Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation
New therapy with unique bacterial strain B. bifidum HI-MIMBb75 promises help for approximately 80 million Europeans suffering from irritable bowel syndrome1 - World's largest clinical OTC irritable bowel syndrome trial investigating the efficacy of this particular strain published in the renowned medical journal The Lancet Gastroenterology & Hepatology2 - Results show significant efficacy for all predominant irritable bowel syndrome symptoms and all subtypes while simultaneously improving patients’ quality of life2 (Gräfelfing/Munich, Germany) The world's largest OTC irritable bowel syndrome (IBS) trial comes up with remarkable results, which were recently published in the renowned medical journal The Lancet Gastroenterology & Hepatology. For the first time, leading German scientists around Prof. Dr. Peter Layer (Israelitic Hospital Hamburg) were able to prove the significant efficacy of a heat-inactivated bacterial strain on patients with IBS. Trial results show that B. bifidum HI-M
Probiotics Applications in Autoimmune Diseases
Global Research Trends and Hot Spots in the Overlapping Fields of Functional Bowel Disorders and the Intestinal Microbiota: A Scientometric Analysis
Gastrointestinal Disorders, Free Full-Text
Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice - Paul Moayyedi, Fermín Mearin, Fernando Azpiroz, Viola Andresen, Giovanni Barbara, Maura Corsetti, Anton Emmanuel, A Pali S Hungin, Peter
Frontiers Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance
A Clostridia-rich microbiota contributes to increased excretion of bile acids in diarrhea-predominant irritable bowel syndrome
Frontiers Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders
Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome
Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
